Skip to main content
S&P 5007,551.81-0.45%DOW51,461.90-1.21%NASDAQ25,978.42-0.01%BTC$76,350.00+0.56%ETH$2,434.62+1.18%GOLD$4,361.80-0.59%OIL$100.73-1.66%
Smart Investors Daily
BioCardia, Inc. logo

NASDAQ · BCDA

BioCardia, Inc.

Healthcare · Biotechnology

$1.25

Up+$0.02 (+1.63%)

Updated Sep 17, 2026, 11:07 AM

SID Score

4.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
8.58M
P/E ratio
-1,087.96
Dividend yield
0.00%
52-week range
$0.75 – $1.80
Volume
1.53M
Avg. volume
598.12K

Price performance

BCDA price history

1M range · 20 trading sessions · Daily adjusted prices

BCDA closed at $1.25 after 20 trading sessions, up 26.14% for the selected period.

Last close
$1.25
Period change
+26.14%
Period low
$0.97
Period high
$1.25
Daily close
View OHLC price history
BCDA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 16, 2026$1.24$1.40$1.13$1.251.53M
Sep 15, 2026$1.19$1.29$1.19$1.23519.88K
Sep 14, 2026$1.10$1.23$1.10$1.19595.64K
Sep 11, 2026$1.12$1.14$1.08$1.08137.03K
Sep 10, 2026$1.09$1.105$1.07$1.1079.96K
Sep 9, 2026$1.1108$1.14$1.09$1.1091.02K
Sep 8, 2026$1.09$1.135$1.08$1.11130.31K
Sep 4, 2026$1.07$1.085$1.06$1.0858.2K
Sep 3, 2026$1.12$1.13$1.07$1.09169.6K
Sep 2, 2026$1.11$1.13$1.10$1.1150.97K
Sep 1, 2026$1.13$1.13$1.08$1.1069.29K
Aug 31, 2026$1.14$1.17$1.10$1.14141.69K
Aug 28, 2026$1.17$1.1958$1.11$1.15159.26K
Aug 27, 2026$1.18$1.23$1.17$1.17211.55K
Aug 26, 2026$1.13$1.2101$1.10$1.19247.12K
Aug 25, 2026$1.06$1.14$1.0201$1.13354.25K
Aug 24, 2026$0.9951$1.06$0.9801$1.06272.56K
Aug 21, 2026$0.973$1.02$0.956$1.0182.46K
Aug 20, 2026$1.00$1.00$0.9501$0.9671156.29K
Aug 19, 2026$0.98$1.03$0.9266$0.991347.28K

Latest BCDA news

The latest Smart Investors Daily articles mentioning BCDA.

Stock researchCompany · Overview

BCDA research

Overview

Company profile and research snapshot.

Company profile

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
BCDA recent ratings
DateFirmRatingTarget
Aug 24, 2026HC Wainwright & Co.Buy—
Jun 9, 2026HC Wainwright & Co.Buy—
Sep 22, 2025HC Wainwright & Co.Buy—
Dec 18, 2024HC Wainwright & Co.Buy—
Nov 14, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 10, 2026

BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference

SUNNYVALE, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that Peter Altman, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will be held at the Lotte New York Palace Hotel in New York City, September 14-16, 2026. Dr. Altman will provide an update

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By